2023-509150-64-00招募中1 期
NXP800 in subjects with Ovarian Cancer
Nuvectis Pharma Inc.4 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2024年3月25日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 8
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Chief Development Officer
Scientific
Nuvectis Pharma Inc.
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
A Clinical Trial of Standard Chemotherapy (weekly Paclitaxel) +/- a novel agent in recurrent ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian CancerEUCTR2014-005221-12-GBHS Greater Glasgow and Clyde140
招募中
不适用
Ovarian cancer ctDNA Nir-Bev studyOvarian cancerjRCT203122073238
已完成
3 期
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)ovarian cancerjRCT2080224597pharmaand GmbH/ CMIC Co., Ltd.100
已完成
不适用
orth Thames CA125 study in advanced ovarian cancerOvarian cancerCancerISRCTN75843298K Co-ordinating Committee for Cancer Research (UKCCCR)237
未知
1 期
Clinical Evaluation of NK211 for Ovarian Cancer <Phase II study>Recurrent ovarian cancerJPRN-jRCT2080220963ippon Kayaku Co., Ltd.